Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2200

Acelyrin says goodbye to the drug that got it a $540M IPO in 2023

$
0
0
Acelyrin is officially ending development of an experimental medicine it referred to as a "diamond in the rough" and that served as the foundation for one of the

Viewing all articles
Browse latest Browse all 2200

Trending Articles